NEW YORK, Jan. 7 (GenomeWeb News) -- PTC Therapeutics of South Plainfield, NJ, announced today the closing of a $35 million Series E round of funding led by CSFB Private Equity and HBM Bioventures.

Additional investors included Bay City Capital, Delphi Ventures, Hansa Special Opportunities Fund Ltd., HealthCap, Novartis BioVentures, Novo A/S, POSCO BioVentures and Vulcan Capital.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.